|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/26/24 Marker Therapeutics, Inc. 10-K 12/31/23 80:9.4M Toppan Merrill/FA2 |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.99M
2: EX-4.0 Instrument Defining the Rights of Security Holders HTML 25K
3: EX-4.1 Instrument Defining the Rights of Security Holders HTML 35K
4: EX-10.8 Material Contract HTML 172K
5: EX-10.9 Material Contract HTML 120K
6: EX-21.1 Subsidiaries List HTML 21K
7: EX-23.1 Consent of Expert or Counsel HTML 22K
12: EX-97 Clawback Policy re: Recovery of Erroneously HTML 46K
Awarded Compensation
8: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
18: R1 Document and Entity Information HTML 92K
19: R2 Consolidated Balance Sheets HTML 109K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 41K
21: R4 Consolidated Statements of Operations HTML 122K
22: R5 Consolidated Statements of Operations HTML 27K
(Parenthetical)
23: R6 Consolidated Statements of Stockholders' Equity HTML 67K
24: R7 Consolidated Statements of Stockholders' Equity HTML 24K
(Parenthetical)
25: R8 Consolidated Statements of Cash Flows HTML 100K
26: R9 Consolidated Statements of Cash Flows HTML 25K
(Parenthetical)
27: R10 Nature of Operations HTML 32K
28: R11 Financial Condition, Going Concern and Management HTML 40K
Plans
29: R12 Significant Accounting Policies HTML 41K
30: R13 Net Loss Per Share Applicable to Common HTML 61K
Shareholders
31: R14 Other Receivable HTML 25K
32: R15 Discontinued Operations HTML 93K
33: R16 Property and Equipment HTML 25K
34: R17 Leases HTML 24K
35: R18 Accounts Payable, Accrued Liabilities, and Related HTML 44K
Party Payable
36: R19 Stockholders' Equity HTML 62K
37: R20 Stock-Based Compensation HTML 109K
38: R21 Grant Income HTML 31K
39: R22 Legal Proceedings HTML 25K
40: R23 Related Party Transactions HTML 47K
41: R24 Income Taxes HTML 93K
42: R25 Subsequent Events HTML 26K
43: R26 Significant Accounting Policies (Policies) HTML 72K
44: R27 Net Loss Per Share Applicable to Common HTML 61K
Shareholders (Tables)
45: R28 Discontinued Operations (Tables) HTML 93K
46: R29 Accounts Payable, Accrued Liabilities, and Related HTML 43K
Party Payable (Tables)
47: R30 Stockholders' Equity (Tables) HTML 49K
48: R31 Stock Based Compensation (Tables) HTML 99K
49: R32 Related Party Transactions (Tables) HTML 37K
50: R33 Income Taxes (Tables) HTML 87K
51: R34 Nature of Operations (Details) HTML 44K
52: R35 Financial Condition, Going Concern and Management HTML 103K
Plans (Details)
53: R36 Significant Accounting Policies (Details) HTML 28K
54: R37 NET LOSS PER SHARE APPLICABLE TO COMMON HTML 83K
SHAREHOLDERS - Computation of loss per Share
(Details)
55: R38 NET LOSS PER SHARE APPLICABLE TO COMMON HTML 30K
SHAREHOLDERS - Dilutive Securities (Details)
56: R39 Other Receivable (Details) HTML 45K
57: R40 DISCONTINUED OPERATIONS - Assets and liabilities HTML 67K
(Details)
58: R41 DISCONTINUED OPERATIONS - Operations (Details) HTML 39K
59: R42 DISCONTINUED OPERATIONS - Service Revenue HTML 39K
(Details)
60: R43 DISCONTINUED OPERATIONS - Additional Information HTML 55K
(Details)
61: R44 Accounts Payable, Accrued Liabilities, and Related HTML 45K
Party Payable (Details)
62: R45 STOCKHOLDERS' EQUITY - Reverse Stock Split and HTML 56K
Common and Preferred Stock Transactions (Details)
63: R46 STOCKHOLDERS' EQUITY - Stock Purchase Agreement HTML 46K
(Details)
64: R47 STOCKHOLDERS' EQUITY - Share Purchase Warrants HTML 32K
(Details)
65: R48 STOCK-BASED COMPENSATION - Stock option activity HTML 63K
(Details)
66: R49 STOCK-BASED COMPENSATION - Weighted average HTML 34K
assumptions (Details)
67: R50 STOCK-BASED COMPENSATION- Stock-based compensation HTML 33K
expenses (Details)
68: R51 STOCK-BASED COMPENSATION - Additional Information HTML 150K
(Details)
69: R52 Grant Income (Details) HTML 55K
70: R53 Related Party Transactions (Details) HTML 40K
71: R54 INCOME TAXES - Summary of Effects of Temporary HTML 35K
Differences that Give Rise to Significant Portions
of the Deferred Tax Assets (Details)
72: R55 INCOME TAXES - Additional Information's (Details) HTML 47K
73: R56 INCOME TAXES - Schedule of expected tax expense HTML 63K
(Benefit) From Continuing Operations (Details)
74: R57 Pay vs Performance Disclosure HTML 34K
75: R58 Insider Trading Arrangements HTML 28K
77: XML IDEA XML File -- Filing Summary XML 133K
80: XML XBRL Instance -- mrkr-20231231x10k_htm XML 1.40M
76: EXCEL IDEA Workbook of Financial Report Info XLSX 132K
14: EX-101.CAL XBRL Calculations -- mrkr-20231231_cal XML 140K
15: EX-101.DEF XBRL Definitions -- mrkr-20231231_def XML 542K
16: EX-101.LAB XBRL Labels -- mrkr-20231231_lab XML 1.06M
17: EX-101.PRE XBRL Presentations -- mrkr-20231231_pre XML 830K
13: EX-101.SCH XBRL Schema -- mrkr-20231231 XSD 155K
78: JSON XBRL Instance as JSON Data -- MetaLinks 412± 617K
79: ZIP XBRL Zipped Folder -- 0001410578-24-000297-xbrl Zip 929K
Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002
I, Juan Vera, certify that:
1. I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: March 25, 2024
| | |
/s/ Juan Vera | | |
By: | | |
Title: | President, Chief Executive Officer and Treasurer | |
| (Principal Financial and Accounting Officer) | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/26/24 | None on these Dates | ||
| Filed on: | 3/25/24 | |||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/26/23 Marker Therapeutics, Inc. 8-K:5,9 1/26/23 11:204K Toppan Merrill/FA 5/27/22 Marker Therapeutics, Inc. 8-K:5,9 5/24/22 11:185K Donnelley … Solutions/FA 8/10/21 Marker Therapeutics, Inc. S-3 8:1.7M Toppan Merrill/FA 11/09/20 Marker Therapeutics, Inc. 10-Q 9/30/20 68:6.4M Toppan Merrill/FA 6/12/20 Marker Therapeutics, Inc. S-8 6/12/20 4:344K Toppan Merrill/FA 3/15/19 Marker Therapeutics, Inc. 10-K 12/31/18 84:10M Toppan Merrill/FA 10/23/18 Marker Therapeutics, Inc. 8-K:1,5,8,910/19/18 5:191K Toppan Merrill/FA 10/17/18 Marker Therapeutics, Inc. 8-K:1,2,3,510/16/18 10:685K Toppan Merrill/FA |